An 8-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase IV Study to Evaluate Dapagliflozin 10 mg Once Daily Effects on Insulin Resistance in Subjects With Type 2 Diabetes Mellitus

Trial Profile

An 8-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase IV Study to Evaluate Dapagliflozin 10 mg Once Daily Effects on Insulin Resistance in Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms DERISC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 31 Mar 2016 Planned End Date changed from 1 May 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
    • 31 Mar 2016 Planned primary completion date changed from 1 May 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top